Page 2 - Ericl Simpson News Today

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many

Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment of atopic dermatitis in adolescents and adults, according to a phase 3 study.“Currently, emollients and topical corticosteroids (TCS) are mainstay treatments for mild AD. In moderate to severe AD, the addition of systemic therapy and/or phototherapy is recommended,” Eric L.

The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.

With no unexpected signals, a recent review of tralokinumab safety out to 1 year found no unexpected signals and provided some information about potential advantages of flexible dosing.

Researchers found no significant relationship between median week 16 dupilumab levels and 1-year clinical responses.

The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study. Adbry (tralokinumab, LEO Pharma) is the only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine, one of the drivers of atopic dermatitis.

Jan 15, 2021 FAMILY FEATURES PHOTO Eczema is a common but annoying disease — in no small part due to its unpredictability. Family Features — More than 30 million Americans, including nearly 10 million children, have eczema, the umbrella term for a group of noncontagious, inflammatory and painful skin conditions marked by an itchy, rash-like appearance. Because one of the most challenging aspects of eczema can be its unpredictability, the National Eczema Association (NEA), designed an app...